§Weight LossResearch protocol
Retatrutide.
Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes[1][2]. Phase 2 trials demonstrated r...
Vial Size:
Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
Cited diluent1 mL
Cited protocol example—review and confirm.
Reference syringe capacity
Concentration
5,000
mcg/mL
Per event
2 mg
1 events/week
Vials projected
—
No finite cited cycle
Calculated volume reference
40.0 units
1mL syringe
Retatrutide
40.0u(0.400 mL)
Once weekly
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–4
2 mg (2000 mcg)
Units / volume40 units (0.40 mL)
Weeks 5–8
4 mg (4000 mcg)
Units / volume80 units (0.80 mL)
Weeks 9–12
6 mg (6000 mcg)
Units / volume120 units (1.20 mL)
Weeks 13+
8 mg (8000 mcg)
Units / volume160 units (1.60 mL)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 40 units (0.40 mL) |
| Weeks 5–8 | 4 mg (4000 mcg) | 80 units (0.80 mL) |
| Weeks 9–12 | 6 mg (6000 mcg) | 120 units (1.20 mL) |
| Weeks 13+ | 8 mg (8000 mcg) | 160 units (1.60 mL) |
Reconstitution by vial size
Calculated volume for each cited phase and vial variant. The highlighted column matches the selection above.
| Phase | 5 mg 1 mL water | 10 mg 1 mL water | 20 mg 2 mL water | 30 mg 3 mL water |
|---|---|---|---|---|
| Weeks 1–4 | 40 u 0.40 mL | 20 u 0.20 mL | 20 u 0.20 mL | 20 u 0.20 mL |
| Weeks 5–8 | 80 u 0.80 mL | 40 u 0.40 mL | 40 u 0.40 mL | 40 u 0.40 mL |
| Weeks 9–12 | 120 u 1.20 mL ×2 vials | 60 u 0.60 mL | 60 u 0.60 mL | 60 u 0.60 mL |
| Weeks 13+ | 160 u 1.60 mL ×2 vials | 80 u 0.80 mL | 80 u 0.80 mL | 80 u 0.80 mL |
Cited guide source: View source